Ovarian Cancer clinical trials in Vermont

4 actively recruiting ovarian cancer trials at 4 sites across Vermont.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology

NCT ID: NCT05879926

Sites in Vermont:

Central Vermont Medical Center/National Life Cancer Treatment — Berlin Corners, Vermont
University of Vermont Medical Center — Burlington, Vermont
University of Vermont and State Agricultural College — Burlington, Vermont
Dartmouth Cancer Center - North — Saint Johnsbury, Vermont

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group

NCT ID: NCT03067181

Sites in Vermont:

Central Vermont Medical Center/National Life Cancer Treatment — Berlin Corners, Vermont
University of Vermont Medical Center — Burlington, Vermont
University of Vermont and State Agricultural College — Burlington, Vermont

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…

Sponsor: Eli Lilly and Company

NCT ID: NCT05768139

Sites in Vermont:

University of Vermont Medical Center — Burlington, Vermont

View on ClinicalTrials.gov →

Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska

NCT ID: NCT02012699

Sites in Vermont:

Rutland Regional Medical Center — Rutland, Vermont

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20